X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AXA1125 has demonstrated an ability to reverse mitochondrial dysfunction and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced inflammation.
Lead Product(s): AXA1125
Therapeutic Area: Musculoskeletal Product Name: AXA1125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
AXA1125 has demonstrated an ability to reverse mitochondrial dysfunction and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced inflammation.
Lead Product(s): AXA1125
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation, at both dose levels of AXA1125.
Lead Product(s): AXA1125
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
AXA1665 is an EMM composition of 8 amino acids and derivatives that targets three key nodes: ammonia toxicity, amino acid imbalance, and muscle wasting.
Lead Product(s): AXA1665
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Axcella intends to use the net proceeds from the offering to complete its Long COVID Phase 2a clinical trial for AXA1125 and, assuming positive data for program; complete enrollment of its EMMPACT Phase 2b clinical trial in NASH; and EMMPOWER Phase 2 clinical trial in OHE.
Lead Product(s): AXA1125
Therapeutic Area: Infections and Infectious Diseases Product Name: AXA1125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 16, 2022
Details:
In two prior successful clinical studies and in preclinical models, AXA1125 has demonstrated an ability to restore mitochondrial function and improve energetic efficiency via increased fatty acid oxidation, restored cellular homeostasis, and reduced inflammation.
Lead Product(s): AXA1125
Therapeutic Area: Immunology Product Name: AXA1125
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
AXA1665-002 was a placebo-controlled, randomized clinical study that investigated the safety, tolerability and physiological impact of AXA1665 in 60 subjects with mild (Child Pugh A) and moderate (Child Pugh B) hepatic insufficiency.
Lead Product(s): AXA1665
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
The new publication details the potential for the development of EMM compositions that simultaneously target multiple biological pathways and address unmet needs in a range of complex diseases.
Lead Product(s): AXA1125
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Poster presentation contains data demonstrating AXA1125’s multifactorial effects on markers of metabolism, inflammation and fibrosis in subjects with NAFLD.
Lead Product(s): AXA1125,AXA1957
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1125
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
Data support AXA1665’s potential to address hyperammonemia, amino acid dysregulation and physical dysfunction in subjects with cirrhosis.
Lead Product(s): AXA1665
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: AXA1665
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
